NT5E and radiation pneumonitis: As data on the PACIFIC regime with additive CD73 targeting from the ongoing PACIFIC-9 trial is still pending, it remains to be ascertained if the incidence rates of radiation pneumonitis reported to date can be confirmed in a larger cohort.